Tolerability and Single Agent Anti-Neoplastic Activity of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory AML or MDS

被引：2

作者：

Watts, Justin M. ^{[1
,2
]}

Lin, Tara L. ^{[3
,4
]}

Mims, Alice S. ^{[5
,6
]}

Patel, Prapti ^{[7
]}

Shami, Paul J. ^{[8
,9
]}

Cull, Elizabeth H. ^{[10
]}

Cogle, Christopher R. ^{[11
]}

Lee, Cynthia ^{[12
]}

Uckun, Fatih ^{[12
]}

机构：

[1] Sylvester Comprehens Canc Ctr, Miami, FL USA

[2] Univ Miami Hlth Syst, Miami, FL USA

[3] Univ Kansas, Med Ctr, Div Hematol Malignancies & Cellular Therapeut, Kansas City, KS 66103 USA

[4] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA

[5] Ohio State Univ, Ctr Comprehens Canc, Arthur G James Canc Ctr Hosp, Columbus, OH 43210 USA

[6] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA

[7] Univ Texas Southwestern Med Ctr, Div Hematol Oncol, Dallas, TX USA

[8] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA

[9] Univ Utah, Huntsman Canc Inst, Div Hematol & Hematol Malignancies, Salt Lake City, UT USA

[10] GHS Canc Inst, Greenville, SC USA

[11] Univ Florida, Dept Med, Gainesville, FL 32610 USA

[12] Aptevo Therapeut, Seattle, WA USA

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-149337

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3415

引用

页数：5

共 50 条

[1] Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436
Uckun, Fatih M.
Watts, Justin
Mims, Alice S.
Patel, Prapti
Wang, Eunice
Shami, Paul J.
Cull, Elizabeth
Lee, Cynthia
Cogle, Christopher R.
Lin, Tara L.
CANCERS, 2021, 13 (21)
[2] Risk and Severity of Cytokine Release Syndrome in Patients with Relapsed/Refractory (R/R) AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436
Lim, Tara L.
Watts, Justn M.
Mims, Alice S.
Patel, Prapti
Shami, Paul J.
Cull, Elizabeth H.
Cogle, Christopher R.
Lee, Cynthia
Uckun, Faith
BLOOD, 2021, 138
[3] Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA
Watts, Justin
Lin, Tara L.
Mims, Alice
Patel, Prapti
Lee, Cynthia
Shahidzadeh, Anoush
Shami, Paul
Cull, Elizabeth
Cogle, Christopher R.
Wang, Eunice
Uckun, Fatih M.
FRONTIERS IN ONCOLOGY, 2022, 11
[4] A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Uckun, Fatih M.
Lin, Tara L.
Mims, Alice S.
Patel, Prapti
Lee, Cynthia
Shahidzadeh, Anoush
Shami, Paul J.
Cull, Elizabeth
Cogle, Christopher R.
Watts, Justin
CANCERS, 2021, 13 (16)
[5] Bispecific Anti-CD123 x Anti-CD3 Adaptir™ Molecules APVO436 and APVO437 Have Broad Activity Against Primary Human AML Cells In Vitro
Godwin, Colin D.
Bates, Olivia M.
Laszlo, George S.
Gottschalk, Rebecca
Comeau, Michael R.
Hoyos, Gabriela H.
Walter, Roland B.
BLOOD, 2017, 130
[6] Preliminary Results from a Phase 1 Study of APVO436, a Novel Anti-CD123 x Anti-CD3 Bispecific Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
Watts, Justin M.
Lin, Tara
Wang, Eunice S.
Mims, Alice S.
Cull, Elizabeth H.
Patel, Prapti A.
Shami, Paul J.
Walter, Roland B.
Cogle, Christopher R.
Chenault, Ruth A.
Macpherson, Bret
Chunyk, Allison Given
McMahan, Catherine J.
Gross, Jane A.
Stromatt, Scott
BLOOD, 2020, 136
[7] Characterization of APVO436, a bispecific anti-CD123 x anti-CD3 ADAPTIR™ molecule for redirected T-cell cytotoxicity, in preclinical models of AML and nonhuman primates
Comeau, Michael R.
Miller, Robert E.
Bannink, Jeannette
Johnson, Starrla
Bader, Robert
Gottschalk, Rebecca
Misher, Lynda
Mitchell, Danielle
Parr, Lara
DeFrancesco, Melissa
Bienvenue, David
McMahan, Catherine J.
Hoyos, Gabriela H.
Gross, Jane A.
MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
[8] Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 Adaptir T Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
Watts, Justin
Maris, Michael
Lin, Tara L.
Patel, Prapti
Madanat, Yazan F.
Cogle, Christopher R.
Borthakur, Gautam
Huebner, Dirk
Khaskhely, Noor
Bonham, Lynn
Massaro, Monica
Taylor, Daphne
Taromino, Caroline
Mims, Alice S.
BLOOD, 2022, 140 : 6204 - 6205
[9] Phase 1 Cohort Expansion of Flotetuzumab, a CD123xCD3 Bispecific Dart® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Uy, Geoffrey L.
Rettig, Michael P.
Vey, Norbert
Godwin, John
Foster, Matthew C.
Rizzieri, David A.
Arellano, Martha L.
Topp, Max S.
Huls, Gerwin
Jongen-Lavrencic, Mojca
Martinelli, Giovanni
Paolini, Stefania
Ciceri, Fabio
Carrabba, Matteo Giovanni
Sweet, Kendra L.
Ravandi, Farhad
Church, Sarah E.
Vadakekolathu, Jayakumar
Rutella, Sergio
Sun, Jichao
Yang, Kang
Baughman, Jan
Curtis, Teia
Timmeny, Erin
Cali, Kerri
Tran, Kathy
Muth, John
La Motte-Mohs, Ross
Poirot, Camille
Pallis, Athanasios
Cesano, Alessandra
Bonvini, Ezio
Wigginton, Jon
Lowenberg, Bob
Davidson-Moncada, Jan K.
DiPersio, John F.
BLOOD, 2018, 132
[10] Immune Landscapes Predict Chemotherapy Resistance and Anti-Leukemic Activity of Flotetuzumab, an Investigational CD123xCD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Vadakekolathu, Jayakumar
Minden, Mark D.
Hood, Tressa
Church, Sarah E.
Reeder, Stephen
Altmann, Heidi
Sullivan, Amy H.
Viboch, Elena J.
Patel, Tasleema
Ibrahimova, Narmin
Warren, Sarah E.
Arruda, Andrea
Schmitz, Marc
Liang, Yan
Cesano, Alessandra
Pockley, A. Graham
Valk, Peter
Lowenberg, Bob
Bornhauser, Martin
Tasian, Sarah K.
Rettig, Michael P.
Davidson-Moncada, Jan K.
DiPersio, John F.
Rutella, Sergio
BLOOD, 2019, 134

← 1 2 3 4 5 →